ATOSSA Aktie

>ATOSSA Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: +1,0%

6 Monate: +699,8%

1 Jahr: +1,0%

laufendes Jahr: +1,0%

>ATOSSA Aktie

Name:

ATOSSA THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US04962H5063 / A2JJ99

Symbol/ Ticker:

YAG2 (Frankfurt) / ATOS (NASDAQ)

Kürzel:

FRA:YAG2, ETR:YAG2, YAG2:GR, NASDAQ:ATOS

Index:

Webseite:

https://atossatherapeutic..

Profil:

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing investigational medicines in oncology and other areas of significant unmet medical need. Its primary focus centers on (Z)-Endoxifen, a proprietary oral selective estrog..
>Volltext..

Marktkapitalisierung:

40.02 Mio. EUR

Unternehmenswert:

4.15 Mio. EUR

Umsatz:

EBITDA:

-32.16 Mio. EUR

Nettogewinn:

-30.12 Mio. EUR

Gewinn je Aktie:

-3.5 EUR

Schulden:

Liquide Mittel:

35.87 Mio. EUR

Operativer Cashflow:

-25.78 Mio. EUR

Bargeldquote:

5.02

Umsatzwachstum:

Gewinnwachstum:

-36.33%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ATOSSA

Letzte Datenerhebung:

04.04.26

>ATOSSA Kennzahlen

Aktien/ Unternehmen:

Aktien: 8.61 Mio. St.

Frei handelbar: 99.69%

Leerverk. Aktien: 3.72%

Rückkaufquote: -

Mitarbeiter: 14

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 241.72%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 1.17

PEG-Ratio: -0.04

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -56.06%

Eigenkaprendite: -62.74%

>ATOSSA Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>ATOSSA Chart & Kurs - NASDAQ

>ATOSSA News

26.03.26 - 05:45	Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 22:33	Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update (PR Newswire)
	SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results for the fourth......

11.02.26 - 14:33	Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook (PR Newswire)
	SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D.,......

05.02.26 - 14:33	Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program (PR Newswire)
	Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company......

30.01.26 - 20:31

XFRA: Deletion of Instruments from Boerse Frankfurt - 30.01.2026 (XETRA)

he following instruments on Boerse Frankfurt do have their last trading day on 30.01.2026. Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.01.2026. ISIN Name CA3397643006 FLORA GROWTH CORP. CA7759041055 ROMIOS GOLD RES INC. CA88605U1075 THUNDERBIRD ENTER.GRP GB00B24CGK77 RECKITT BENCK.GRP LS -,10 GG00BP2NJT37 TAYLOR MARITIME LTD. SE0018040784 CINIS FERTILIZER AB SE0025012032 VIRTUNE AB O.END ETP BTC US02919L7038 AME.REB.HLD.INC. O.N. US03828A1016 APPLIED THERAPEUTDL-,0001 US0463531089 ASTRAZENECA DL-,25 SP.ADR US04962H5063 ATOSSA THERAPEU. DL -,015 US12740C1036 CADENCE BANK DL 2,5 US17253J1144 CIPHER MINING WTS26 US2003401070 COMERICA INC. DL 5 US26740W1172 D-WAVE QUATUM WTS27 US7495271071 REV GROUP INC. DL-,001...

30.01.26 - 17:54

XFRA: ISIN Change (XETRA)

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen US04962H5063 Atossa Therapeutics Inc . 30.01.2026 US04962H7044 Atossa Therapeutics Inc. 02.02.2026 Tausch 15:1 US02919L7038 American Rebel Holdings Inc. 30.01.2026 US02919L8028 American Rebel Holdings Inc. 02.02.2026 Tausch 20:1 CA3397643006 Zerostack Corp. 30.01.2026 CA98956L1013 Zerostack Corp. 02.02.2026 Tausch 1:1 GG00BP2NJT37 Taylor Maritime Ltd. 30.01.2026 GG00BTZC2850 Taylor Maritime Ltd. 02.02.2026 Tausch 100:54 CA7759041055 Romios Gold Resources Inc. 30.01.2026 CA68616A1003 Romios Gold Resources Inc. 02.02.2026 Tausch 10:1 GB00B24CGK77 Reckitt Benckiser Group PLC 30.01.2026 GB00BSZBP530 Reckitt Benckiser Group PLC 02.02.2026 Tausch 25:24...

21.01.26 - 15:06	Atossa Therapeutics′ Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 (PR Newswire)
	Recognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology SEATTLE, Jan. 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies......

16.01.26 - 22:42	Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy (PR Newswire)
	Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage......

16.01.26 - 12:42	Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.01.26 - 14:18	Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer (PR Newswire)
	SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") issued a "Study May Proceed" letter for......

17.12.25 - 14:18	Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category (PR Newswire)
	Recognized for Advancing (Z)-Endoxifen, a Precision-Engineered Endocrine Therapy with Potential Across Multiple Breast Cancer and Rare Disease Settings SEATTLE, Dec. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage......

11.12.25 - 16:42	Atossa gains on Rare Pediatric Disease status for Duchenne asset (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.12.25 - 15:18	Atossa Therapeutics: Aktie springt nach FDA-Sonderstatus für Medikamentenkandidaten an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.12.25 - 14:03	Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy (PR Newswire)
	Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval SEATTLE, Dec. 11, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage......

17.11.25 - 15:12	Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation (PR Newswire)
	Published article outlines rationale for multi-pathway efficacy for (Z)-endoxifen in Duchenne Muscular Dystrophy (DMD); November scientific presentation to spotlight potential in Duchenne carrier–associated pathologies SEATTLE, Nov. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc.......

12.11.25 - 14:18	Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
	Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities, including a Type C meeting with the FDA, to potentially accelerate (Z)-endoxifen in breast cancer risk reduction......

21.10.25 - 14:03	Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents (PR Newswire)
	Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS SEATTLE, Oct. 21, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the......

14.10.25 - 14:15	Atossa Therapeutics appoints CFO to support commercial transition (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.10.25 - 14:06	Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals (PR Newswire)
	Portfolio covers high-purity Z-endoxifen enteric formulations, performance characteristics, and manufacturing methods, part of Atossa's multi-jurisdiction IP strategy to support clinical and commercial plans SEATTLE, Oct. 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS)......

06.10.25 - 14:06	Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities (PR Newswire)
	Changes are expected to reduce future study costs, accelerate objective readouts, and extend operating runway under current plans SEATTLE, Oct. 6, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company), a clinical-stage biopharmaceutical company developing......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram